hotspot -WSS

hotspot

author：hotspot 2025-09-28 01:30:41 - browse：8

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Man killed during FBI raid in connection with threats against Biden, other officials

WSS

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Why failed clinical trials don’t always spell doom for a new drug

Health tech startups drop sharply from 2021 highs

Researchers use wearables data and AI to predict preterm birth risk

Data show record exodus of life scientists from academia

What to know about Virgin Galactic's 1st mission taking paying customers to space

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

entertainment

Apple is now the first public company to be valued at $3 trillion

Health tech startups drop sharply from 2021 highs

Continuity nursing helped my family in our darkest PICU moments

Friends ask where James Watson's attitudes about race came from

Hepatitis C has a cure — but many Americans still lack access to it

Address the ethical violations that led to 'Three Identical Strangers'

The high cost of giving birth even with insurance

Intercept Pharmaceuticals sells itself for less than $1 billion

Malaria cases in Florida and Texas: Here’s what you need to know

How to use technology to prevent future drug shortages

hotspot

Sudafed saga points to U.S. issues with evaluating older drugs

Researchers use wearables data and AI to predict preterm birth risk

How one patient went off dialysis — and others can too

Wegovy’s successful heart trial raises vital question about weight loss

In same hospitals, Black patients receive fewer opioids than white patients

Sudafed saga points to U.S. issues with evaluating older drugs

Wikipedia

explore

hotspot

focus